Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IF Anyone goes into the weekend WITHOUT Solid Size, the chase next week will be extreme. All the clues were in that last pr!! Much headed our way ANYDAY NOW, EVEN AFTERHOURS TODAY IS A POSSIBILITY!
OUR NEW CEO ENDORSED BY NASDAQ COMPANY VP Tomasz H. Zastawny, PhD, DSc, who is highly skilled in Biotechnology! Vice President, Head of Clinical Operations at Epizyme WHICH IS NASDAQ LISTED $EPZM $13 per share
BOOM! ALSO Joseph Cotropia has been ENDORSED by Tomasz H. Zastawny, PhD, DSc, who is highly skilled in Biotechnology! Vice President, Head of Clinical Operations at Epizyme WHICH IS NASDAQ LISTED $EPZM $13 per share
LET THIS SINK IN: BioClonetics FINAL stage of development of a parent monoclonal antibody ("mAbs") (designated as Clone 3), which is non-toxic & has shown in initial in vitro testing 2 B Effective against More than 95% of ALL Strains & viral subtypes of HIV-1 against which it's been tested
BioClonetics INVITED by the National Science Foundation (NSF) 2 submit an application 4 funding 4 development of anti-SARS-Cov-2 monoclonal antibodies using its proprietary #Technology. Such application to the NSF & a corresponding application to the NIH R NOW PENDING
The Company is also looking to expand its medical advisory board with individuals that have direct experience taking medical products through the regulatory process and bringing them to market.
PATENTSSSS Between the two Companies is worth MANY MANY MILLIONS ALONE
Jim King #CTO Held the position CIO at S&P Global, Inc., NYSE $SPGI $351 A SHARE! 6 BILLION REVENUES! You think he knows how to operate?? Holy shit!
Nice!! 4 Patents between the 2 Companies and I just got that feeling, MORE Monster News is not far off, especially after reading this:
We were recently (within the last 3 weeks) asked by Bravo Healthcare, Ltd. (https://bravopharma.com) to partner with them in an application to CEPI (https://cepi.net) to produce a vaccine against the Coronavirus. As you know, this virus has caused a critical worldwide health crisis facing all countries. Because of the urgency of the medical and related financial costs posed by this virus, the call by CEPI for applications for therapies to address the situation was open for only a very short period. Our application was filed yesterday February 13, 2020.
• Those entities joining in our application include:
o Bravo Healthcare Ltd., bravopharma.com
o Rihim Pharma, rihimpharma.com
o JSS Medical Research, jssresearch.com
o IcosagenLtd, icosagen.com
o University of Tartu, ut.ee
o University of California, universityofcalifornia.edu
• CEPI (pronounced “seppy”) has as its objective the acceleration of development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks. It is an organization founded in Davos, Switzerland by the governments of Norway and India, the Gates Foundation, the Wellcome Trust and the World Economic Forum. It has secured $760 Million toward its $1 Billion Funding target, with multi year funding from Norway, UK, Germany, japan, Canada, Ethiopia, Australia and the Gates Foundation and Wellcome Trust. It also has received single-year installments from Belgium, and the European Commission. Our partner in this application, Bravo Pharma is headquartered in Europe and Estonia.
• Why were we contacted by Bravo to partner in this program? The Coronavirus has structure corresponding to that of the HIV virus. Because our monoclonal antibody has been shown to neutralize the HIV virus in 5 international lab testing programs, and because we know the structure to which the antibody binds resulting in neutralization, this knowledge provides insight necessary to identifying the structure (amino acid sequence) we consider the corresponding “Achilles Heel” of the Coronavirus. From this knowledge, a phage display vaccine is proposed to be produced and tested against the virus. We have a working relationship with the California Animal Trials Center at the University of California for testing the proposed vaccine or, due to the urgency of the situation, direct clinical trials could be approved. Production and delivery of a successful vaccine would be carried out by the other partners to the application.
We are working diligently to make progress, and we extend our sincere appreciation for your support.
Best regards,
Charles Cotropia
CEO
BioClonetics Immunotherapeutics, Inc.
Grabbing more of what I can today before next week! Betting another PR is on the way. That last pr has many items to look for in the SHORT TERM!! Good day all
MOST IMPORTANT IN MANAGEMENT WITH MONSTER TIES IS... Jim King #CTO VNUE,Inc
Held the position CIO at S&P Global, Inc., $SPGI $351 A SHARE! 6 BILLION REVENUES! CTO for RELX Group Plc. Inc., LISTED, CTO for LexisNexis Group, Inc., CTO at Broadcast Music, Inc. & CTO at Brightpoint WHICH was 5.24 BILLION
Louis Mann, 69
Director & Executive Vice President, VNUE, Inc.
Founder of VNUE, Inc., Louis Mann holds the position of President, Secretary & Director at Broadcasting Institute of Maryland, Inc. and Chief Operating Officer & Director at Unified Natural Product Solutions, Inc. Mr. Mann is also Director & Executive Vice President at VNUE, Inc.
Mr. Mann previously was Senior Vice President-Marketing at Mca Records, Inc., President, Secretary & Director at Tierra Grande Resources, Inc., Senior Vice President of Capitol Industries-EMI, Inc. and President-Media Properties Division at House of Blues Entertainment LLC.
He received an undergraduate degree from the University of Maryland and an MBA from the University of California, Los Angeles.
CONNECTIONS
https://zachbair.com/ I’ve worked for all kinds of amazing companies in various roles, such as American Airlines/Sabre, Sprint, Nortel, Marathon Oil, and others, including EDS as a management consultant. I have started multiple companies, including Voyence, which sold to EMC Corporation, and Immediatek, which sold to Mark Cuban. I also started RockHouse Live Media Productions, Inc., which owns the DiscLive Network brand (above), and that company is still in operation. I have been working in the music business now (tech focused) since 2002, a the CEO level.
Nice!! 4 Patents between the 2 Companies and I just got that feeling, MORE Monster News is not far off, especially after reading this:
We were recently (within the last 3 weeks) asked by Bravo Healthcare, Ltd. (https://bravopharma.com) to partner with them in an application to CEPI (https://cepi.net) to produce a vaccine against the Coronavirus. As you know, this virus has caused a critical worldwide health crisis facing all countries. Because of the urgency of the medical and related financial costs posed by this virus, the call by CEPI for applications for therapies to address the situation was open for only a very short period. Our application was filed yesterday February 13, 2020.
• Those entities joining in our application include:
o Bravo Healthcare Ltd., bravopharma.com
o Rihim Pharma, rihimpharma.com
o JSS Medical Research, jssresearch.com
o IcosagenLtd, icosagen.com
o University of Tartu, ut.ee
o University of California, universityofcalifornia.edu
• CEPI (pronounced “seppy”) has as its objective the acceleration of development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks. It is an organization founded in Davos, Switzerland by the governments of Norway and India, the Gates Foundation, the Wellcome Trust and the World Economic Forum. It has secured $760 Million toward its $1 Billion Funding target, with multi year funding from Norway, UK, Germany, japan, Canada, Ethiopia, Australia and the Gates Foundation and Wellcome Trust. It also has received single-year installments from Belgium, and the European Commission. Our partner in this application, Bravo Pharma is headquartered in Europe and Estonia.
• Why were we contacted by Bravo to partner in this program? The Coronavirus has structure corresponding to that of the HIV virus. Because our monoclonal antibody has been shown to neutralize the HIV virus in 5 international lab testing programs, and because we know the structure to which the antibody binds resulting in neutralization, this knowledge provides insight necessary to identifying the structure (amino acid sequence) we consider the corresponding “Achilles Heel” of the Coronavirus. From this knowledge, a phage display vaccine is proposed to be produced and tested against the virus. We have a working relationship with the California Animal Trials Center at the University of California for testing the proposed vaccine or, due to the urgency of the situation, direct clinical trials could be approved. Production and delivery of a successful vaccine would be carried out by the other partners to the application.
We are working diligently to make progress, and we extend our sincere appreciation for your support.
Best regards,
Charles Cotropia
CEO
BioClonetics Immunotherapeutics, Inc.
Night all, things to get done
Agree Q7! I am loving all the Patents these 2 Companies hold along with SUCCESSFUL RESULTS
Killer find UncleBilly! Davos is the world's biggest economic event.
$ENZC pic.twitter.com/rEI7JHaN4z
— Cheers (@crabbermike) September 17, 2020
3 PATENTS OWNED BY BIOCLONETICS IMMUNOTHERAPEUTICS, INC.
Patent Owner
http://www.patentbuddy.com/Company/Profile/BIOCLONETICS-IMMUNOTHERAPEUTICS-INC./261995
Great day. Loaded more dips throughout the day, toward the end of the day. Saying tomorrow is going to be one of the last days this trades under .01 Next week I am betting on some very big news. DD The players on LinkedIn and ties, endorsements!!!
Copper next week I bet. Hell, tomorrow could be insane due to the fact that it may be tough getting size if they drop an update, especially on funding! Boooom
I BET It is and will be a done deal. This just did not happen. Many months have been invested by both parties already. Just read up on the players involved! Pennies next week as we should be seeing much more very soon.
This merger is gonna PRODUCE SOME BIG PR's VERY VERY SOON!
BioClonetics said that because of the similar structures of HIV and COVID-19 and the efficacy of its Clone 3 antibody in fighting HIV, the company has been asked by the National Science Foundation @NSF to submit a funding application for development of a COVID-19 antibody. The company currently has applications pending with the NSF and the National Institutes of Health.
Remember, this was months ago. Betting they got PLENTY TO TELL IN THE NEAR TERM!!! INSANE OPPORTUNITY
Gotta say, I have not seen this much Potential in a Company and Stock in a long time. What have they been working on behind the scenes blows my mind! HIV, Corona with major ties to big name people and Universities, ie Harvard and Duke!! Wait till next week
Great post Q7! Absolutely massive potential going forward. Good day
If people are pissed they missed the run, they have no clue. The upside is 1000'S of percentages to come. Do your DD. Look at ALL the players on LinkedIn, the HUGE Ties to other individuals and Companies. Insane next month ahead
Such application to the NSF and a corresponding application to the NIH are now pending.
At BioClonetics Immunotherapeutics, we’re one step closer to ending the search for the HIV cure. We have discovered and developed a proprietary cell line that produces a fully-human antibody proven to specifically target and effectively neutralize HIV-1. These validating tests were conducted at Harvard Medical School, Duke University, Univ. of Calif. San Francisco, Univ. of South Florida and Polymun Scientific.
Charles S. Cotropia of BioClonetics Immunotherapeutics, Inc. HAS MASSIVE TIES TO MANY in PATENT LITIGATION, INTELLECTUAL PROPERTY, TRADEMARKS!! HUGE ENDORSEMENTS POSTED ON HIS LINKEDIN PAGE
Did you check out Joseph Cotropia on LinkedIn? Endorsed by
Endorsed by Tomasz H. Zastawny, PhD, DSC Epizyme NASDAQ Traded EPZM $12.76
MAXIMUM 10 TRADING DAYS LEFT TO BUY ALL U CAN! BETTING WE SEE THE BOTTLING PLANT UP AND RUNNING PRIOR TO OCT 1ST FOR THIS GAMECHANGER THEY CALL OXY-BLAST 50!! DEMAND WILL BE HUGE, BEGINNING WITH....KROGER! SEE IF I AM RIGHT. GROCERY STORE DEMAND IS GOING TO BE HUGE, ADDING EVEN BIGGER REVENUES AND PROFIT MARGINS!!
GOOD DAY ALL
Betting on More News This Week Sometime. See if I am Right!! LOL!, thanks for cheapies. Later
MONSTER PROFIT MARGINS TO BOOT! WHOOP WHOOP! When OXY-BLAST 50 LAUNCHES BY OCT 1, BOOOM SHAKA-LAKA
Kiawah island club I contacted. They are a 7 million dollar Company using Oxi-thyme from @OxiThyme
I contacted Gillian through their website, Member Services.
All going great with Oxi-thyme
NEW YORK CITY OXI-THYME IS UP AND RUNNING PER StockRockets PHONE CALL!! EXTREMELY BUSY.
GROWTH GROWTH GROWTH FOLKS!!